Login / Signup

Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes.

Piia LavikainenEmma AarnioKari JalkanenHilkka TirkkonenPäivi RautiainenTiina LaatikainenJanne Martikainen
Published in: BMC health services research (2020)
Simultaneously with the increase of the co-payment level, the average HbA1c level increased among T2D patients from the North Karelia region, Finland. This may be explained by the decreased consumption of diabetes medications between 2016 and 2017. Special attention should be allocated to glycaemic control of patients utilizing only other antidiabetic medications than metformin or insulin.
Keyphrases
  • type diabetes
  • end stage renal disease
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • cardiovascular disease
  • metabolic syndrome
  • patient reported outcomes
  • adipose tissue